Ends 01/2019 Council

The emphasis is on targeting, metabolism, effectiveness, toxicology, biodistribution, breakdown products and pathological findings for imaging cells, tissues, organs, or whole body in animals and humans. These studies often involve radiochemistry, pharmacokinetics, and pharmacodynamics.

 

The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.

Topics


  • The development of targeted MRI probes, using paramagnetic, nanoparticle, hyperpolarized or other contrast mechanisms, and the development of instrumentation that is uniquely required for probe-based imaging.
  • The development of targeted molecular imaging agents detectable with X-ray based modalities.
  • Development of targeted optical imaging agents, including fluorescence, bioluminescence, photosensitizer, and agents for photoacoustic imaging.
  • Development of diagnostic and therapeutic agents and carriers including radiopharmaceutical agents.
  • Novel reporter gene strategies for imaging of gene expression and inter-molecular interactions in vivo.
  • Live cell imaging including cell trafficking, improved labeling methods, mechanistic studies, physiologic processes, and distribution.
  • Translational and clinical toxicity, as well as biodistribution of agents and their breakdown products, which may involve radiochemistry, pharmacokinetic and pharmacodynamic studies of imaging agents.

Shared Interests and Overlaps

There are shared interests with Medical Imaging (MEDI) in the development of image based surrogate endpoints and conduction of pre-clinical and clinical trials of medical imaging systems. Grant applications that focus on the synthesis, development, biodistribution, and pharmacokinetics of imaging agents may be assigned to CMIP. Applications that focus on applications of the imaging systems, diagnosis of functional disorders, image guided interventions, or prediction, selection, or monitoring of therapeutic response may be assigned to MEDI.

There are shared interests with Biomedical Imaging Technology (BMIT A) / Biomedical Imaging Technology (BMIT B) in the development of image based biomarkers and conduction of imaging studies at the cellular, organ, animal, or human scale. Grant applications that focus on synthesis, development, biodistribution, and pharmacokinetics of imaging agents may be assigned to CMIP. Applications that focus on hardware and software components, image formation, analysis, evaluation, or validation may be assigned to BMIT A/B.

There are shared interests with Radiation Therapy and Radiopharmaceuticals (RTB) in the investigation of imaging and image analysis as related to targeting of radiation and response assessment in addition to conduct of preclinical studies to model radiation therapeutics. Grant applications that focus on synthesis, development, biodistribution, and pharmacokinetics of imaging agents may be assigned to CMIP. Applications that focus on proof of principle, treatment planning physics, mechanisms, or basic molecular/cellular interactions may be assigned to RTB.

There are shared interests with Synthetic and Biological Chemistry A (SBCA ) in the investigation of synthetic methodologies and syntheses of biologically relevant targets. Grant applications that focus on synthesis, development, biodistribution, and pharmacokinetics of imaging agents may be assigned to CMIP. Applications that focus on the fundamental levels of chemical biology, nucleic acid chemistry, carbohydrate chemistry, supramolecular chemistry, or metal chemistry may be assigned to SBCA.

There are shared interests with Synthetic and Biological Chemistry B (SBCB) in the investigation of synthetic methodologies and syntheses of biologically relevant targets including bioactive small molecules to probe biological systems. Grant applications that focus on synthesis, development, biodistribution, and pharmacokinetics of imaging agents may be assigned to CMIP. Applications that focus on the fundamental levels of chemical biology, peptide and protein chemistry, or natural product biosynthesis and discovery may be assigned to SBCB.

There are shared interests with Cellular and Molecular Technologies (CMT) in the synthesis of probes for the study of cellular and molecular processes. Grant applications that focus on the development of probes for whole animal and clinical imaging may be assigned to CMIP. Applications that focus on development of probes for cell-level investigations, including NMR detectable probes, may be assigned to CMT.

There are shared interests with Enabling Bioanalytical and Imaging Technologies (EBIT) in the chemical synthesis of probes for use with bioanalytical or biophysical technologies. Grant applications that focus on synthesis, development, biodistribution, and pharmacokinetics of imaging agents for a translational or clinical application may be assigned to CMIP. Applications that focus on bioanalytical techniques, biophysical techniques, or software development and application may be assigned to EBIT.

There are shared interests with Nanotechnology (NANO) in the synthesis and evaluation of nanoparticles for cellular imaging and theranostics. Grant applications that focus on synthesis, development, biodistribution, and pharmacokinetics of imaging agents, including theranostics, may be assigned to CMIP. Applications that focus on the fundamental levels of nanotechnology or nanomaterials may be assigned to NANO. ​